Navigation Links
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
Date:10/31/2007

NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. (Other OTC: RXAF.PK), announced today that effective immediately, its stock will now trade under the symbol RXAF.PK and that the name "Diamond Entertainment" and its symbol (DMON.PK) will no longer be used as part of the company's operations.

Rx for Africa, Inc. is the surviving company in a reverse merger completed in May 2007 with Diamond Entertainment Corp. - (DMON.PK). Through its wholly owned subsidiary, Rx Africa (Ethiopia) PLC (formerly known as Sunshine Pharmaceutical), Rx for Africa, Inc. owns and operates a state-of-the art pharmaceutical plant built on twenty three thousand square meters of land located south of Addis Ababa, Ethiopia. The Company is currently producing and marketing eight generic products in Ethiopia, with the goal of increasing production within the next 12 to 18 months to 50 products meeting US Food and Drug Administration (US FDA) and World Health Organization (WHO) good manufacturing practices (GMP). The expected product list includes three malaria drugs, three drugs for tuberculosis, nine HIV drugs, 27 antibiotics, and several each of anti-protozoans, anti-fungals and anti-emetics.

"The change in our name and symbol to Rx Africa, Inc. (RXAF.PK) better reflects our mission and focus as a world-class provider of generic medicines, including those for HIV/AIDS, malaria, tuberculosis and other diseases," commented Dr. Mulugetta Bezzabeh, CEO of Rx Africa (Ethiopia) PLC and board member of Rx for Africa, Inc. "Though presently focused solely in Ethiopia, we plan to expand our distribution throughout sub-Saharan Africa and beyond, and our new name and symbol are properly reflective of our path and vision. We are going to be a major player in the African pharmaceutical business."

For further information contact:

Howard Becker, Director

Rx for Africa, Inc.

(917) 553-1205

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
6. Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles
7. Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
8. MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy
9. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):